<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of ocular irAEs in patients treated with immune checkpoint inhibitors*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of ocular irAEs in patients treated with immune checkpoint inhibitors*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of ocular irAEs in patients treated with immune checkpoint inhibitors*</div><div class="cntnt"><table cellspacing="0"><colgroup width="35%"></colgroup><colgroup width="65%"></colgroup> <tbody> <tr> <td class="subtitle1_single" colspan="2">10. Ocular toxicities</td> </tr> <tr> <td class="indent1" colspan="2">Evaluation, under the guidance of ophthalmology: <ul class="decimal_heading"> <li>Check vision in each eye separately.</li> <li>Color vision.</li> <li>Red reflex.</li> <li>Pupil size, shape, and reactivity.</li> <li>Fundoscopic examination.</li> <li>Inspection of anterior part of eye with penlight.</li> <li>Slitlamp examination.</li> <li>Eye pressure.</li> <li>Need to rule out myasthenia gravis.</li> </ul> Prior conditions: <ul class="decimal_heading"> <li>Exclude patients with history of active uveitis.</li> <li>History of recurrent uveitis requiring systemic immunosuppression or continuous local therapy.</li> </ul> Additional considerations: <ul class="decimal_heading"> <li>Clinicians should be aware that ocular irAEs commonly accompany other organ irAEs, and there should be a high level of clinical suspicion, as symptoms may not always be associated with severity. Patients with all grades of ocular symptoms should be referred to ophthalmology.</li> </ul> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">10.1. Uveitis or iritis</td> </tr> <tr> <td class="indent1" colspan="2">Work-up and evaluation: as per 10.0: <ul class="decimal_heading"> <li>Ophthalmology consult should be universal for the symptoms described in 10.0.</li> </ul> </td> </tr> <tr> <td class="subtitle2">Grading</td> <td class="subtitle2">Management</td> </tr> <tr> <td class="indent1">G1: Anterior uveitis with trace cells.</td> <td> <ul> <li>Continue ICPi.</li> <li>Prompt referral to ophthalmology (usually within 1 week).</li> <li>Artificial tears.</li> </ul> </td> </tr> <tr> <td class="indent1">G2: Anterior uveitis with 1+ or 2+ cells.</td> <td> <ul> <li>Hold ICPi temporarily until after ophthalmology consult.</li> <li>Urgent ophthalmology referral.</li> <li>Topical corticosteroids (eg, 1% prednisolone acetate suspension), cycloplegic agents (eg, atropine), and systemic corticosteroids.</li> <li>May resume ICPi treatment once off systemic steroids if patient has only ocular irAE, once corticosteroids are reduced to ≤10 mg/day prednisone equivalent. Continued topical or ocular steroids are permitted when resuming therapy to manage and minimize local toxicity.</li> <li>Retreat after return to ≤G1.</li> </ul> </td> </tr> <tr> <td class="indent1">G3: Anterior uveitis with 3+ or greater cells; intermediate posterior or pan-uveitis.</td> <td> <ul> <li>Permanently discontinue ICPi.</li> <li>Urgent ophthalmology referral.</li> <li>Systemic corticosteroids and intravitreal or periocular/or topical corticosteroids.</li> <li>Methotrexate may be used in patients who respond poorly to systemic corticosteroids or those with severe sight-threatening inflammation.</li> </ul> </td> </tr> <tr> <td class="indent1">G4: Best-corrected visual acuity of 20/200 or worse in the affected eye.</td> <td> <ul> <li>Permanently discontinue ICPi.</li> <li>Emergent ophthalmology referral.</li> <li>Systemic corticosteroids – prednisone 1 to 2 mg/kg/day or methylprednisolone 0.8 to 1.6 mg/kg/day and intravitreal or periocular or topical corticosteroids per ophthalmologist opinion.</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2">Additional considerations: <ul class="decimal_heading"> <li>Consider use of infliximab, other TNF-alpha blockers, or IVIG in cases that are severe and refractory to standard treatment.</li> </ul> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">10.2. Episcleritis</td> </tr> <tr> <td class="indent1" colspan="2">Work-up and evaluation: as per 10.0.</td> </tr> <tr> <td class="subtitle2">Grading</td> <td class="subtitle2">Management</td> </tr> <tr> <td class="indent1">G1: Asymptomatic.</td> <td> <ul> <li>Continue ICPi.</li> <li>Prompt ophthalmology referral (usually within 1 week).</li> <li>Artificial tears.</li> </ul> </td> </tr> <tr> <td class="indent1">G2: vision 20/40 or better.</td> <td> <ul> <li>Hold ICPi therapy temporarily until after ophthalmology consult.</li> <li>Urgent ophthalmology referral.</li> <li>Topical corticosteroids (eg, 1% prednisolone acetate suspension), cycloplegic agents (eg, atropine), and systemic corticosteroids.</li> </ul> </td> </tr> <tr> <td class="indent1">G3: Symptomatic and vision worse than 20/40.</td> <td> <ul> <li>Permanently discontinue ICPi.</li> <li>Urgent ophthalmology referral.</li> <li>Systemic corticosteroids and topical corticosteroids with cycloplegic agents.</li> </ul> </td> </tr> <tr> <td class="indent1">G4: 20/200 or worse.</td> <td> <ul> <li>Permanently discontinue ICPi.</li> <li>Emergent ophthalmology referral.</li> <li>Systemic corticosteroids and topical corticosteroids with cycloplegic agents.</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2">Additional considerations: <ul class="decimal_heading"> <li>Consider use of infliximab or other TNF-alpha blockers in cases that are severe and refractory to standard treatment.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">irAE: immune-related adverse event; 
	ICPi: immune checkpoint inhibitor; 
	IVIG: intravenous immune globulin; 
	TNF: tumor necrosis factor.<br/>
	
	* The American Society of Clinical Oncology (ASCO) guidelines are intended to provide initial guidance in the management of treatment-related side effects. Consultation with appropriate specialists may be indicated.</div><div class="graphic_reference">From: Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073. DOI: <a href="https://ascopubs.org/doi/full/10.1200/JCO.21.01440" target="_blank">10.1200/JCO.21.01440</a>. Copyright © 2022 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 116764 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
